

# ALTA VISTA VENTURES LTD.

AVV – CSE  
News Release #16-1

January 22, 2016

## **Alta Vista brings on George Smitherman to the Board, Kim Derry as Senior Advisor – Safety and Security and Don Shaxon as Senior Advisor.**

Alta Vista Ventures Ltd. ('Alta Vista' or the 'Company') (AVV-CSE, YRLLF-OTC) announces that Mr. George Smitherman has joined its Board of Directors and that Mr. Kim Derry has joined the Company as Senior Advisor – Safety and Security.

Mr. Smitherman had a long successful political career until 2010 when he returned to his pre politics roots as an entrepreneur. He is the founder of three companies and is an advisor to several others. Most recently a candidate for the Mayor of Toronto, Mr. Smitherman has previously been elected three times as a Member of the Provincial Parliament where he served as Ontario's Deputy Premier, Health Minister, Minister of Energy and Infrastructure as well as many other roles. Over a career spanning almost 25 years Mr. Smitherman has been active in all three levels of government.

Mr. Smitherman's interest in Medical Marijuana started when he was Ontario's Health Minister. He has since become a vocal advocate of Medical Marijuana and the legalization of recreational marijuana nationally.

Mr. Kim Derry has had a long distinguished career in law enforcement. Over his 38 year career Mr. Derry has performed uniform, undercover and investigative duties. At the peak of his law enforcement career Mr. Derry was appointed the Deputy Chief of Police for the City of Toronto. He has been responsible for the policing operations in Toronto for 17 divisions, managed in excess of 4,000 personnel and oversaw divisional policing budgets of \$490 million.

Mr. Derry's wide ranging experience in safety and security is a natural fit for the Marijuana for Medical Purposes Regulations (MMPR) environment. He is motivated by the opportunity to reduce the influence of gangs and organized crime through a sensible regulatory regime.

In addition, the Company would like to announce that Mr. Don Shaxon is also joining as Senior Advisor. Mr. Shaxon brings 20 years' experience in the capital markets including and in the Medical Marijuana sector since 2007. As Corporate development Manager with Cannabis Science Inc., the first public company in North America dedicated to the marijuana industry he helped build the company from a small cap company into an industry leader with a market cap that topped \$100 million. Since then he has been involved in a number of public companies and was instrumental in bringing the RedeCan Pharm opportunity to the Company.

### **About Alta Vista Ventures:**

The purchase of Redecan Pharm is a critical step in Alta Vista's goal of becoming a significant player in Canada's medical marijuana marketplace. Under the terms of the LOI, subject to satisfactory due diligence and the signing of a definitive agreement, Alta Vista Ventures can purchase a 100% undivided interest in RedeCan Pharm by paying \$7,000,000 in cash and issuing a total of 7,575,757 shares. In addition to the purchase price Alta Vista will pay a 10% royalty of the gross revenues of RedeCan on a quarterly basis to be paid 50% in cash and 50% in shares of Alta Vista.

**Alta Vista Ventures Ltd.**

459 – 409 Granville St., Vancouver, BC, Canada V6C 1T2 ■ telephone: 604-678-2531 ■ facsimile: 604-678-2532

# ALTA VISTA VENTURES LTD.

In addition to the right to purchase RedeCan, Alta Vista has the right to purchase Thor Pharma, an early stage MMPR applicant that could add up to 75,000 square feet of growing space. Alta Vista cannot guarantee nor estimate the timing for the issuance of an MMPR license to Thor Pharma.

As part of its ongoing efforts to expand in the sector Alta Vista continues to evaluate additional opportunities.

On behalf of the Board,

*“Ian Foreman”*

Ian Foreman  
President

For information on Thor Pharma and RedeCan please contact Mr. Don Shaxon at 289-697-8625.

For additional information on Alta Vista Ventures please call the Company at 604-678-2531.

Neither Canadian Securities Exchange (CSE) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

*Statements in this press release, other than purely historical information, including statements relating to the Company's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in such statements. As a result, actual results may vary materially from those described in the forward-looking statements.*